GlassScriptPhysician profile
Janusz Luka
NPI 1598732919
$4,406.00
in general payments reported to CMS, 2019-2025
23 companies · $1,026 in 2025
The $1,026 reported for 2025 was more than what 91% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $251 · 2020: $314 · 2021: $407 · 2022: $869 · 2023: $950 · 2024: $589 · 2025: $1,026.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,465 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,465.22 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $887.01 | 2019-2025 | Clareon, Hydrus Microstent, Lensx |
| Biotissue Holdings INC. | $538.26 | 2020-2025 | |
| Oyster Point Pharma, INC. | $478.36 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Novartis Pharmaceuticals Corporation | $299.71 | 2019-2023 | |
| Kala Pharmaceuticals, INC. | $252.66 | 2020-2022 | |
| Mallinckrodt Hospital Products INC. | $246.34 | 2022-2025 | Acthar |
| Sun Pharmaceutical Industries INC. | $233.29 | 2021-2024 | Cequa |
| Johnson & Johnson Vision Care, INC. | $183.51 | 2019-2024 | Acuvue |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $167.69 | 2019-2021 | |
| Abbvie INC. | $162.27 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $160.73 | 2022-2025 | Vyzulta, Lotemax Sm, Zylet |
| Sight Sciences, INC. | $120.54 | 2020 | |
| Shire North American Group INC | $99.54 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $92.39 | 2024-2025 | Xdemvy |
| Amgen INC. | $89.20 | 2025 | Tepezza |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $66.06 | 2024-2025 | Vevye |
| Aerie Pharmaceuticals, INC. | $62.88 | 2019-2021 | |
| Allergan, INC. | $61.60 | 2019-2022 | |
| Dompe US, INC. | $58.07 | 2025 | Oxervate |
| Horizon Therapeutics Plc | $55.75 | 2022-2023 | Tepezza |
| Thea Pharma INC. | $37.45 | 2022-2024 | Iyuzeh |
| Johnson & Johnson Surgical Vision, INC. | $33.52 | 2019-2020 | |
| Merz Pharmaceuticals, LLC | $19.17 | 2025 | Xeomin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janusz Luka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.